The Cost-Effectiveness of Fluvastatin in Hungary Following Successful Percutaneous Coronary Intervention
- 16 June 2006
- journal article
- Published by Springer Science and Business Media LLC in Cardiovascular Drugs and Therapy
- Vol. 20 (4), 309-317
- https://doi.org/10.1007/s10557-006-8877-3
Abstract
Background The Lescol Intervention Prevention Study (LIPS) showed substantial gains in health outcomes from statins following PCI. That study was a randomized double-blind placebo-controlled trial undertaken in 77 centres, predominantly in Europe, of patients with moderate hypercholesterolemia who had undergone their first PCI. The evidence on cost-effectiveness has been established for the UK, USA and the Netherlands, but due to different health system cost structures, the results may not be applicable to other European countries. The aim of this study was to estimate the cost-effectiveness of fluvastatin used following first PCI in Hungary. Materials and methods A deterministic Markov model was used to estimate the incremental costs per quality-adjusted life year gained, with cost data drawn from the Hungarian National Health Insurance Fund. Effectiveness data on fluvastatin was derived directly from LIPS and utility weights from previous studies on heart disease. Sensitivity analyses were conducted around key parameters and analyses were conducted for subgroups identified in LIPS. Results Treatment with fluvastatin cost an additional €1,704 and resulted in an additional 0.107 QALYs per patient discounted over 10-years compared with controls. The incremental cost per quality-adjusted life year gained was €15,910. The key determinants of cost-effectiveness were the effectiveness of fluvastatin, utility weights, cost of fluvastatin, and the time horizon evaluated. Fluvastatin was substantially more cost-effective in patients with diabetes, renal disease, multi-vessel disease or LDL-cholesterol >3.4 mmol/l. Conclusions Fluvastatin is an economically efficient pharmaceutical for reducing heart disease in Hungary and other European countries in patients following PCI.Keywords
This publication has 24 references indexed in Scilit:
- Highlighting the need for better patient care in stable angina: results of the international Angina Treatment Patterns (ATP) Survey in 7074 patientsFamily Practice, 2004
- An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UKPharmacoEconomics, 2004
- A single European currency for EQ-5D health statesThe European Journal of Health Economics, 2003
- Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) studyAmerican Heart Journal, 2003
- Quality of life and time trade-off utility measures in patients with coronary artery diseaseAmerican Heart Journal, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?Published by Oxford University Press (OUP) ,2001
- Comparison of Coronary-Artery Bypass Surgery and Stenting for the Treatment of Multivessel DiseaseNew England Journal of Medicine, 2001
- Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.The American Journal of Cardiology, 1998
- Markov Models in Medical Decision MakingMedical Decision Making, 1993